Objectives Nicotine metabolism rates differ considerably among individuals, even after controlling for variation in the major nicotine-metabolizing enzyme, CYP2A6. In this study, the impact of genetic variation in alternative metabolic enzymes and transporters on nicotine and cotinine (COT) pharmacokinetics and smoking was investigated.
Methods We examined the impact of UGT2B10, UGT2B17, FMO3, NAT1, and OCT2 variation on pharmacokinetics and smoking (total nicotine equivalents and topography) before and after stratifying by CYP2A6 genotype in 60 African American (AA) smokers who received a simultaneous intravenous infusion of deuterium-labeled nicotine and COT.
Results Variants in UGT2B10 and UGT2B17 were associated with urinary glucuronidation ratios (glucuronide/ free substrate). UGT2B10 rs116294140 was associated with significant alterations in COT and modest alterations in nicotine pharmacokinetics. These alterations, however, were not sufficient to change nicotine intake or topography. Neither UGT2B10 rs61750900, UGT2B17*2, FMO3 rs2266782, nor NAT1 rs13253389 altered nicotine or COT pharmacokinetics among all individuals (n = 60) or among individuals with reduced CYP2A6 activity (n = 23). The organic cation transporter OCT2 rs316019 significantly increased nicotine and COT C max (P = 0.005, 0.02, respectively) and decreased nicotine clearance (P = 0.05).
UGT2B10 rs116294140 had no significant impact on the plasma or urinary trans-3′-hydroxycotinine/COT ratio, commonly used as a biomarker of CYP2A6 activity.
Conclusion We found that polymorphisms in genes other than CYP2A6 represent minor sources of variation in nicotine pharmacokinetics, insufficient to alter smoking in AAs. The change in COT pharmacokinetics with UGT2B10 rs116294140 highlights the UGT2B10 gene as a source of variability in COT as a biomarker of tobacco exposure among AA smokers. Pharmacogenetics and Genomics 27:143-154 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
African American (AA) smokers have higher tobaccorelated disease risk despite smoking on average fewer cigarettes per day compared with European Americans (EA) [1] [2] [3] . They also differ in the average rate of nicotine metabolism [4] , which is an important determinant of smoking behavior [5] , and smoking-induced disease risk [6] .
Nicotine, the main psychoactive compound in cigarettes [7] , is primarily inactivated by the liver CYP2A6 enzyme to cotinine (COT), which undergoes further CYP2A6-mediated metabolism to trans-3′-hydroxycotinine (3HC) [8] . The ratio of plasma 3HC/COT, known as the nicotine metabolite ratio, is a validated biomarker of CYP2A6 enzymatic activity [9, 10] . Large ethnic differences in the rate of nicotine and COT metabolism, as well as the frequency of CYP2A6 gene variants exist between AAs and EAs [10] [11] [12] [13] . CYP2A6 reduced or null-activity variants such as CYP2A6*17, *20, *23-*28, and *35 are found at a higher frequency in AAs compared with EAs, leading to lower nicotine clearance in AAs [14] [15] [16] . Less is known about the contribution of nicotine-metabolizing enzymes other than CYP2A6 toward nicotine clearance, smoking behavior, and tobacco-induced disease risk among AAs.
UDP-glucuronosyl transferase 2B10 (UGT2B10) catalyzes nicotine N′-glucuronidation, a pathway responsible for 3-5% of total nicotine urinary recovery [17] [18] [19] , which can be as high as 40% in smokers who have deleted CYP2A6 [20] . The same is true for flavin-containing monoxygenase (FMO)-3 enzyme, which catalyzes Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).
nicotine N′-oxidation, a pathway responsible for 4-7% of total nicotine urinary recovery [8] , which increases in individuals with deleted CYP2A6 [21] . This suggests a potentially greater reliance on alternative nicotinemetabolizing pathways mediated by UGT2B10 or FMO3 when CYP2A6 activity is reduced.
A missense mutation in UGT2B10 (rs61750900) reduces nicotine and COT glucuronidation metabolic ratios [most often expressed as glucuronidated metabolite/free substrate or glucuronidated metabolite/total nicotine equivalents (TNE)] in EA smokers during ad libitum smoking [22, 23] or at a single time-point following oral administration of labeled nicotine-d2 [23] . Among AAs, nicotine glucuronidation ratios are lower than those in EAs [24, 25] . Two previously identified UGT2B10 gene variants, the missense mutation (rs61750900) and a splice variant (rs116294140), lead to reductions in nicotine and COT glucuronidation ratios [24] [25] [26] [27] . More recently, in a genome-wide association study (GWAS) of nicotine and COT glucuronidation ratios (glucuronidated metabolite/ total substrate), the most significant hit on 4q13 was strongly correlated with the same UGT2B10 splice variant, whereas another chromosome 4q13 hit was correlated with rs61750900 [27] . Here, we aimed to assess the impact of these two variants on nicotine and COT pharmacokinetic parameters, including clearance. Studies have not, as yet, examined the role of these two UGT2B10 variants, or variants in FMO3, in the pharmacokinetics of intravenously administered nicotine and its primary metabolite, COT, among AA smokers.
We also examined the impact of variation in UGT2B17, an enzyme responsible for O′-glucuronidation of 3HC [28] , and OCT2, a basolateral-type organic cation transporter that mediates tubular secretion of nicotine [29] , on nicotine and COT pharmacokinetics among AAs. Recently, LeMasters et al. [30] reported a potential role for N-acetyltransferase 1 (NAT1) gene in the metabolic pathway of nicotine. Therefore, we aimed to study the impact of NAT1 polymorphisms on nicotine and COT pharmacokinetics. In addition, we investigated whether variation in glucuronidation, N′-oxidation, or transport pathways, which could differentially influence 3HC and COT levels, altered the ratio of 3HC/COT, leading to inaccurate phenotyping of CYP2A6 activity among AAs. Finally, as changes in nicotine pharmacokinetics alter smoking behavior such as consumption and topography, we tested whether variation in alternative nicotine metabolism genes was sufficient to alter measures of smoking.
Methods
Sixty AA smokers completed a nicotine and COT pharmacokinetic study as described previously [31] . Participants' demographic and pharmacokinetic characteristics are presented in Supplementary Table-S1, Supplemental digital content 1, http://links.lww.com/FPC/B189.
Briefly, participants smoked their usual brand of cigarettes supplied by the study for 7 days before the start of the 4-day pharmacokinetic study. They abstained from cigarettes starting at 10 p.m. on the night before infusion. In a fasting condition, at about 9 a.m., participants received a simultaneous 30-min infusion of deuteriumlabeled nicotine-d2 and COT-d4 (2.0 µg/kg/min). Urine and blood samples were collected and plasma nicotine-d2 was assessed in samples collected at 0, 10, 20, 30, 45, 60, 90, 120, 180, 240, 360, and 480 min and at 12, 16, 24, 48 , and 72 h after the infusion. COT and 3HC levels (unlabeled, d2, and d4) from the 360 min plasma sample were used for the determination of the 3HC/COT ratio [9] . This study was approved by the Institutional Review Board at the University of Toronto and the University of California San Francisco.
Participants were previously genotyped for CYP2A6 reduced or null-activity variants found widely among different ethnic groups, CYP2A6*2, *4, *9, and *12, as well as those found predominantly in AAs, CYP2A6*17, *20, *23-*28, *31, and *35 [31] [32] [33] . Individuals with no identified CYP2A6 gene variants were grouped as wild type (*1/*1). To examine the contribution of pathways other than CYP2A6-mediated C-oxidation toward nicotine metabolism, those having at least one CYP2A6 genetic variant with reduced or null-activity were considered to have reduced CYP2A6 activity (n = 23), which included those with CYP2A6*1/*2 (n = 1), *1/*4H (n = 2), *1/*9 (n = 2), *1/*17 (n = 8), *1/*24 (n = 1), *1/*26 (n = 1), *1/*27 (n = 1), *1/*35 (n = 3), *4/*17 (n = 1), *9/*26 (n = 1), *17/*31 (n = 1), *17/*35 (n = 1) genotypes, as described previously [31, 34, 35] .
Genotyping for UGT2B10 splice variant (rs116294140) and nonsynonymous single nucleotide polymorphisms (SNPs) (rs61750900), UGT2B17 deletion variant (*2), FMO3 nonsynonymous SNP (rs2266782), NAT1 intronic SNP (rs13253389), and OCT2 nonsynonymous SNP (rs316019) were performed using TaqMan SNP genotyping assays from Applied Biosystems (Foster City, California, USA).
Plasma nicotine and COT concentrations were measured by gas chromatography-mass spectrometry [36] . 3HC concentrations in plasma and nicotine, COT, 3HC, and nicotine N-oxide concentrations in urine were determined by liquid chromatography-tandem mass spectrometry [9] . Concentrations of nicotine, COT, and 3HC glucuronides in urine were measured as the difference in analyte concentrations before (free) and after (total) enzymatic hydrolysis, as described previously by Benowitz et al. [37] . The limits of quantification for nicotine, COT, and 3HC in plasma were 0.1 ng/ml. The limits of quantification for the urine analytes were 10 ng/ ml for nicotine, COT, 3HC, and nicotine N-oxide and 1 ng/ml for minor species (nornicotine, norcotinine, COT N-oxide).
Model-independent methods were used to estimate pharmacokinetic parameters using blood concentration and urinary nicotine and metabolite data [34] . Nicotine clearance was computed as: CL NIC = Dose NIC-d2 / AUC NIC-d2 , where Dose is the dose of nicotine-d2 infused and AUC is the area under the plasma nicotined2 concentration-time curve extrapolated to infinity. COT clearance was computed the same way using COTd4 dose and AUC [31] . Glucuronidation and N′-oxidation ratios were calculated using the ratio of urinary metabolites to the free parent compound excreted.
Pharmacokinetic means and urinary glucuronidation and N′-oxidation ratios were compared using a nonparametric Mann-Whitney test and the Kruskal-Wallis test between genotype groups. The Bonferroni method was used to correct for multiple testing across five gene variants using a significance threshold of 0.01. Standard regression modeling, assuming a dominant effect of the minor allele, was used to determine the percentage of variance in the pharmacokinetic parameters explained by each gene variant. Considering that d2-labeled and d4-lableled COT and 3HC were not in steady state, the unlabeled plasma 3HC/COT ratio measured at the 360 min time point was used as a biomarker of CYP2A6 activity in the regression models. TNE was calculated based on the creatinine-corrected molar sum of all unlabeled nicotine metabolites excreted in a 24-h urine collection during ad libitum smoking. Urinary nicotine metabolite ratios were also calculated on the basis of unlabeled metabolites excreted during this 24-h urine collection. Percent variance in the pharmacokinetic parameter explained by the genotype or the phenotype is calculated on the basis of the square value of the part correlation coefficients.
Results
UGT2B10 rs116294140 and rs61750900 allele frequencies were 38.3 and 3.3%, respectively. UGT2B17*2, FMO3 rs2266782, NAT1 rs13253389, and OCT2 rs316019 allele frequencies were 31.7, 39.2, 32.5, and 7.5%, respectively. All variants examined were reduced or null-function variants as described in Supplementary Table-S2, Supplemental digital content 1, http://links.lww.com/FPC/ B189. All frequencies were in Hardy-Weinberg equilibrium and consistent with previous reports in AAs [38] [39] [40] .
Effect of UGT2B10 and UGT2B17 genotypes on nicotine and cotinine glucuronidation ratios
We examined the effect of UGT2B10 and UGT2B17 variations on urinary glucuronidation phenotypes using the ratio of nicotine glucuronide to free nicotine or COT glucuronide to free COT as phenotypic measures of UGT2B10 activity and the ratio of 3HC glucuronide to free 3HC as a phenotypic measure of UGT2B17 activity. The impact of functional polymorphisms in UGT2B10 (rs61750900) and UGT2B17*2 on nicotine, COT, and 3HC glucuronidation ratios has been reported previously in human liver microsomes or urine of smokers [19,22-25, 27,41] , and is replicated here as positive controls for the impact of UGT2B10 and UGT2B17 variations on nicotine and COT pharmacokinetics, which has not been tested previously.
The primary role of UGT2B10 as the catalyst of nicotine and COT N′-glucuronidation was confirmed by the effect of UGT2B10 rs116294140 and rs61750900 on both nicotine and COT glucuronide ratios (Fig. 1) . Individuals homozygous for rs116294140 and heterozygous for rs61750900 showed significantly lower nicotine and COT glucuronide ratios compared with wild types (Fig. 1) . Similarly, the 3HC glucuronide ratio was significantly lower in individuals with the variant genotypes ( Fig. 1) .
Effect of UGT2B10 and UGT2B17 genotypes on nicotine and cotinine disposition kinetics
We examined the association between two functional polymorphisms in UGT2B10 and nicotine and COT pharmacokinetics. Although not statistically significant, among all participants (n = 60), we observed a small increase in nicotine half-life and a corresponding decrease in nicotine nonrenal and total clearance in homozygous carriers of UGT2B10 rs116294140 (CC genotype) compared with wild types (AA genotype) ( Table 1 and Fig. 2 ). Among individuals with reduced CYP2A6 activity (n = 23), there was a nonsignificant increase in nicotine half-life and a decrease in nicotine nonrenal and total clearance in homozygous carriers of UGT2B10 rs116294140 compared with wild types (Table 2) . We found no association between UGT2B10 rs61750900 and nicotine pharmacokinetics among all participants or among individuals with reduced CYP2A6 activity (Tables 1 and 2). COT pharmacokinetics were markedly altered by UGT2B10 rs116294140: individuals who were homozygous for rs116294140 had 58% higher COT AUC, 55% lower COT nonrenal clearance, and 44% lower COT total clearance (Table 3 and Fig. 2) . No other associations were observed between UGT2B10 rs61750900 and UGT2B17*2 and COT pharmacokinetics (Table 3) .
Using standard multiple regression models, with the number of minor allele copies entered as the predictor, we found that UGT2B10 rs116294140 explained ∼ 4% of variance in nicotine pharmacokinetics after controlling for variation in CYP2A6, FMO3, OCT2, and UGT2B10 rs61750900. UGT2B10 rs116294140 and rs61750900 together accounted for 5-6% of variation in nicotine pharmacokinetics ( Table 4 ). The contribution of UGT2B10 rs116294140 toward COT pharmacokinetics, however, was more substantial, explaining up to 14% of variance in COT AUC, nonrenal, and total clearance after taking into account variations in CYP2A6, FMO3, OCT2, and UGT2B10 rs61750900 ( Table 5) . As expected (Tables 1-3) , neither UGT2B10 rs61750900 nor UGT2B17*2 made significant contributions toward nicotine or COT pharmacokinetics, respectively; less than 3% of the variance in nicotine or COT pharmacokinetics was explained by UGT2B10 rs61750900 or UGT2B17*2 (Tables 4 and 5 ). It is noteworthy that findings from standard multiple regression models including or excluding the unlabeled plasma 3HC/COT ratio were similar. Mean SEM nicotine-glucuronide/free nicotine and cotinine-glucuronide/free cotinine ratios according to the UGT2B10 rs116294140 genotype (a, d) and according to the UGT2B10 61750900 genotype (b, e) are shown; Mean SEM 3HC glucuronide/free 3HC ratio according to the UGT2B17*2 genotype is shown in (g); Mean SEM nicotine N-oxide/free nicotine ratio according to the FMO3 rs2266782 genotype is shown in (h). UGT2B10 rs116294140 and rs61750900 genotypes were combined in (c, f). Group 1: includes individuals who are wild type for both variants (n = 18); group 2: includes individuals who are wild type for rs61750900 and heterozygous variant for rs116294140 (n = 32); group 3: includes individuals who are heterozygous variant for rs61750900 and wild type for rs116294140 (n = 2); group 4: includes individuals who are heterozygous for both variants (n = 2); and group 5: includes individuals who are wild type for rs61750900 and homozygous variant for rs116294140 (n = 6). All P-values indicated were derived from Mann-Whitney U-test comparing UGT2B10 rs61750900 GG and GT genotypes or Kruskal-Wallis tests comparing UGT2B10 rs116294140, UGT2B17*2, FMO3 rs2266782, and UGT2B10 rs116294140 and rs61750900 combined genotypes. c Nicotine (d2) half-life is measured in min, C max in ng/ml, AUC in min µg/ml, and nonrenal and total clearance in l/min. d Genotype frequencies are presented in the brackets. e OCT2 variation was examined with respect to nicotine renal as opposed to nonrenal clearance (ml/min).
Fig. 2
Mean SEM nicotine (a-d) and cotinine (e-h) AUC, half-life, nonrenal, and total clearance according to the UGT2B10 rs116294140 genotype is shown; All P-values indicated were derived from Kruskal-Wallis test comparing UGT2B10 rs116294140 genotypes. Percent change is calculated based on the value of (CC genotype -AA genotype)/AA genotype. AUC, area under the curve; CL, clearance; COT, cotinine; NIC, nicotine. Arithmetic means are presented. c Nicotine (d2) half-life is measured in min, C max in ng/ml, AUC in min µg/ml, and nonrenal and total clearance in l/min. Genotype frequencies are presented in the brackets. e OCT2 variation was examined with respect to nicotine renal as opposed to nonrenal clearance (ml/min). c Cotinine (d4) half-life is measured in min, C max in ng/ml, AUC in min µg/ml, and nonrenal and total clearance in ml/min. d Genotype frequencies are presented in the brackets. e OCT2 variation was examined with respect to cotinine renal as opposed to nonrenal clearance (ml/min).
Effect of FMO3 and NAT1 genotypes on nicotine and cotinine pharmacokinetics
To examine the effect of FMO3 variation on the N′-oxidation phenotype, we used the urinary ratio of nicotine N-oxide to free nicotine as a measure of FMO3 activity. The FMO3 rs2266782 AA and GA genotypes were associated, albeit nonsignificantly, with lower nicotine N-oxide to free nicotine ratio (36-44% lower vs. wild-type GG genotype) (Fig. 1 ). There was a 10% reduction in nicotine nonrenal and total clearance in homozygous variant individuals (AA genotypes) compared with wild types (GG genotypes). The impact on other nicotine (Table 1) and COT (Table 3 ) pharmacokinetic parameters was negligible in all participants or in individuals with reduced CYP2A6 activity ( Table 2 ). Regression analyses confirmed that the contribution of FMO3 rs2266782 toward variance in nicotine (Table 4) or COT (Table 5 ) pharmacokinetics is negligible among AAs, with less than 3.0% of variance in any pharmacokinetic parameter explained by the FMO3 rs2266782 genotype.
Furthermore, in contrast to the findings of LeMasters et al. [30] , we found no impact of the NAT1 rs13253389 polymorphism on total COT levels or any of the COT pharmacokinetic parameters (Supplementary Table-S3 , Supplemental digital content 1, http://links.lww.com/FPC/ B189).
Effect of the OCT2 genotype on nicotine and cotinine pharmacokinetics
Next, we examined the association between the organic cation transporter, OCT2, genotype, and nicotine and COT pharmacokinetics. The OCT2 CA genotype was associated with a doubling in nicotine C max (Table 1 ) and a 20% increase in COT C max compared with the CC genotype (Table 3) . There was also a trend toward lower nicotine total clearance, but not renal clearance, among individuals with the CA genotype compared with wild types. The OCT2 genotype explained 18% of variance in nicotine C max , 9% of variance in nicotine total clearance, and an additional 9% of variance in COT C max (Tables 4  and 5 ).
Effect of variation in UGT2B10, UGT2B17, and FMO3 on the plasma and urinary 3HC/COT ratio Given that AAs have lower 3HC/COT and glucuronidation metabolic ratios compared with EAs [24, 25] , we examined whether the presence of UGT and FMO3 gene variants alters 3HC/COT in this population. We calculated the plasma 3HC/COT ratio at 360 min on the basis of the metabolites generated from tobacco use (unlabeled or d0) as well as d2-labeled and d4-labeled compounds. The unlabeled, d2-labeled, and d4-labeled ratios were highly correlated with each other (P < 0.001), with a Pearson's partial coefficient, r, of 0.92 (d2 vs. d4), 0.88 (d0 vs. d2), and 0.90 (d0 vs. d4). Albeit nonsignificantly, UGT2B10 rs116294140 was associated with a reduction in unlabeled plasma 3HC/COT ratio and in d2-labeled and d4-labeled ratios, but had no impact on the urinary ratios (Table 6 ). UGT2B17 and FMO3 did not significantly alter the unlabeled, d2-labeled, d4-lableled, or urinary 3HC/ COT ratios ( Table 6 ).
Effect of UGT2B10 rs116294140 on biomarkers of smoking behavior
On the basis of the effect of the UGT2B10 rs116294140 genotype on nicotine clearance, albeit modest, which has been previously shown to affect smoking, we investigated its impact on biomarkers of tobacco consumption and smoking topography (i.e. urine TNE, number of puffs, average puff volume, and total puff volume). TNE is an excellent biomarker of daily nicotine uptake and total tobacco smoke exposure [8, 42] and is calculated as the molar sum of urinary concentration of nicotine and all of its metabolites. Consistent with the modest, nonsignificant reduction in nicotine clearance, we found no significant impact of UGT2B10 rs116294140 on TNE or on smoking topography variables (Fig. 3) , suggesting that the changes in nicotine clearance with UGT2B10 rs116294140 are not sufficient to result in altered smoking behavior among AA smokers. This is consistent with findings from a GWAS study where genetic variation in nicotine and COT glucuronidation ratios was not significantly associated with TNE [27] .
Discussion
We present data on the functional significance of genetic variation in nicotine metabolism pathways other than C-oxidation, such as glucuronidation and N′-oxidation, on nicotine and COT pharmacokinetics in AAs where these variants are prevalent. Variants in the main nicotinemetabolizing gene, CYP2A6, alter nicotine pharmacokinetics in EAs [34] , and AAs [31] . AAs have a higher prevalence of low-frequency reduced and loss-offunction CYP2A6 alleles, suggesting that variations in alternative nicotine metabolism pathways might play a larger role in altering nicotine pharmacokinetics among AAs. Overall, we found a potential influence of variation in UGT2B10-mediated glucuronidation and no influence of variation in FMO-3-mediated N-oxidation pathways on nicotine pharmacokinetics among AAs, and a major influence of variation in UGT2B10-mediated glucuronidation on COT pharmacokinetics.
The most common UGT2B10 SNP in AAs is a splice variant (rs116294140), which is rare among EAs (allele frequency <1%) [43] . The frequency of this splice variant was 38% in this study, similar to the 37% reported previously (NHLBI Exome Sequencing project, accessed 23 Table 6 Plasma and urinary nicotine metabolite ratio by UGT2B10, UGT2B17, and FMO3 genotypes Plasma 3HC/COT ratios at 360 min based on the metabolites generated from tobacco use that is, unlabeled (d0) as well as d2-labeled, and d4-labeled compounds are presented.
June 2016). The rs116294140 has been described as a splice acceptor site between intron 2 and exon 3, which likely results in a UGT2B10 mRNA without exon 3 [44] . Such an mRNA has not been described previously in publicly available databases, suggesting that perhaps this SNP results in undetectable mRNA. Among 364 AAs, UGT2B10 rs116294140 was shown to account for the majority of the reduced nicotine glucuronide levels compared with smokers of other ethnicities [24] . Similarly, in our study, individuals who were homozygous for UGT2B10 rs116294140 excreted little to no nicotine or COT glucuronide. We found a small, nonsignificant gene-dose effect on increasing nicotine half-life and a resulting decrease in nicotine clearance with UGT2B10 rs116294140. The modest decrease in nicotine clearance among UGT2B10 rs116294140 homozygous variants compared with wild types, however, was not sufficient to change smoking behavior such as consumption or smoking topography as observed previously [27] .
The UGT2B10 rs116294140 considerably altered COT pharmacokinetics. This is consistent with a GWAS study where the UGT2B10 locus was highly associated with COT levels among smokers [45] . COT has a low hepatic extraction ratio, suggesting that its clearance is primarily dependent on the amount and activity of metabolic enzymes such as CYP2A6 and UGT2B10. The reason for the more modest effect of the UGT2B10 rs116294140 variant on nicotine pharmacokinetics may be nicotine's high hepatic extraction, resulting in its clearance being more dependent on other factors such as hepatic blood flow [46] . The effect of UGT2B10 rs116294140 on COT pharmacokinetics may explain why AAs have particularly low COT clearance compared with Asians, both of whom have similarly decreased nicotine clearance compared Mean SEM of TNE (nmol/l), puff number, total puff volume (ml), and average puff volume (ml) according to the UGT2B10 rs116294140 genotype (a-d) is shown. Mean TNE (3026 nmol/l AA, 3023 nmol/l AC, 3057 nmol/l CC), mean puff number (12 AA, 13 AC, 15 CC), mean total puff volume (549 ml AA, 562 ml AC, 479 CC), and mean average puff volume (47.4 ml AA, 47.5 AC, 33.0 CC). All P-values indicated were derived from Kruskal-Wallis test comparing UGT2B10 rs116294140 genotypes. TNE, total nicotine equivalents.
Nicotine kinetics in African Americans
with EAs [7] . COT is the most widely used biomarker of tobacco, nicotine, and carcinogen intake among regular smokers [46] ; lower COT glucuronidation ratios in AA smokers compared with other ethnicities have been noted previously [24, 25] . Any given COT level may not represent the same nicotine intake between races with different frequencies of CYP2A6 gene variants [47] . Using pharmacokinetic data, we also show here that COT levels may be misleading when compared among those with differing UGT2B10 rs116294140 genotypes within a race, that is, COT levels may overestimate tobacco exposure in AAs with UGT2B10 rs116294140 variants.
UGT2B17 catalyzes the O-glucuronidation of 3HC, the main nicotine metabolite detected in smokers' urine, but individuals who are homozygous null for UGT2B17 still excreted 3HC glucuronide, albeit significantly less than individuals with two active copies of this gene. The small amount of 3HC glucuronide excreted in homozygous null individuals could be the product of UGT2B7, which is a minor enzyme in the 3HC O′-glucuronidation pathway [41] .
FMO3 rs2266782 is associated with reduced activity; thus, a significant reduction in the nicotine N′-oxide/free nicotine ratio with increasing copies of the FMO3 rs2266782 variant allele was expected, but not observed. It is possible that enzymes other than FMO3 are involved in nicotine N′-oxidation and compensate for the lack of activity among those with FMO3 variants. Consistent with the lack of effect on N′-oxidation ratios, we observed no impact of FMO3 rs2266782 on nicotine or COT pharmacokinetics among all participants or among those with reduced CYP2A6 activity. It is likely that FMO3 rs2266782 is a very minor source of variation in nicotine metabolism, insufficient to significantly alter nicotine or COT pharmacokinetics in AA smokers.
The OCT2 rs316019 CA genotype was associated with significantly higher nicotine and COT C max , which was unexpected, given that labeled nicotine-d2 and COT-d4 were administered intravenously. The functional impact of the OCT2 rs316019 variant is unclear. Those with the OCT2 rs316019 minor allele showed reduced metformin clearance (in a laboratory study of 15 Chinese [48] ) and reduced cisplatin-related nephrotoxicity (among 78 Dutch and 53 Japanese cancer patients [49, 50] ), but was also associated with reduced metformin plasma levels (among 23 individuals [51] ). Here, among 60 AA smokers, OCT2 rs316019 was associated with a nonsignificant, modest decrease in nicotine clearance. The increase in nicotine C max in individuals with this variant, without a considerable effect on nicotine renal clearance, suggests a depot effect where those with the variant have potentially reduced tissue uptake of nicotine, for example into skeletal muscle or the brain.
The ratio of 3HC/COT has been used widely as a biomarker of CYP2A6 activity, and of nicotine and COT clearance. Considering that variation in UGT2B10 and UGT2B17 altered COT and 3HC glucuronidation ratios, respectively, we investigated the potential effect of variation in these genes on the 3HC/COT ratio. Genetic variation in UGT2B10 was associated with a small, nonsignificant reduction in plasma, but not urinary, 3HC/COT ratio. Moreover, the 3HC/COT ratio was essentially unaffected by variation in FMO3 or UGT2B17 genes.
Despite being the largest study of nicotine and COT pharmacokinetics in AAs, our analysis is limited by small sample sizes in some genotype groups. Moreover, because of low power, we could not investigate the effects of combined glucuronidation and N-oxidation variation (UGT/FMO3 genotypes) on nicotine and COT pharmacokinetics.
In summary, among AAs, variation in UGT2B10 was associated with a small, nonsignificant impact on nicotine pharmacokinetics, no impact on smoking (TNE and topography), but a considerable impact on COT pharmacokinetics. Therefore, variation in glucuronidation contributes toward changes in the widely used tobacco exposure biomarker, COT, among AAs and may lead to overestimation of tobacco exposure in AAs compared with smokers of other races.
on issues related to light cigarettes. R.F.T. has served as paid consultant to Apotex. For the remaining authors there are no conflicts of interest.
